Home › Research › Digital health tools
Genomics link obesity and type 2 diabetes to Alzheimers disease to unveil novel biological insights
Cunha, C.; Garcia-Urena, M.; Martinez, R.; Romero-Lado, M. J.; Fernandez, M. V.; Andreassen, O. A.; Sims, R.; Tsolaki et al.. medRxiv (preprint), 2026-08-17
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Body mass index (BMI), type 2 diabetes (T2D) and related cardiometabolic features associate with Alzheimers disease (AD) risk, yet shared mechanisms remain poorly understood. By combining multi-trait, machine learning and single-cell transcriptomics with genotyping data for BMI and T2D, we investigate how these traits converge on shared genetic pathways to AD risk. Variant-level analyses reveal AD risk associates with genetically-driven hypotension and hypoglycaemia. We identify sixteen high-confidence effector genes in seven independent loci colocalizing between BMI/T2D and AD, mapping primarily to peripheral immune-metabolic tissues and cell-types. Eight high-confidence risk genes are currently targeted by ongoing therapeutic programmes, substantiating translatability relevance. Exploratory approaches using sex- and age-stratified genotyping data for BMI and T2D pinpoints potential sex-specific cardiometabolic liability linked to higher BMI-associated risk in women and T2D-driven risk in men. These findings elucidate shared cardiometabolic correlates with AD, prioritizes biological pathways, and reveal computationally-nominated drug candidates for preclinical testing.
What this study adds
Evidence grade: Low
This genomic analysis linked obesity and type 2 diabetes to Alzheimer's disease through shared genes, mostly in peripheral immune and metabolic tissues, and nominated drug candidates for preclinical testing. The findings are computational and have not been tested as treatments in people.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cunha, C., Garcia-Urena, M., Martinez, R., Romero-Lado, M. J., Fernandez, M. V., Andreassen, O. A., et al. (2026). Genomics link obesity and type 2 diabetes to Alzheimers disease to unveil novel biological insights. medRxiv (preprint). https://doi.org/10.64898/2026.02.10.26344393
Vancouver
Cunha C, Garcia-Urena M, Martinez R, Romero-Lado MJ, Fernandez MV, Andreassen OA, et al. Genomics link obesity and type 2 diabetes to Alzheimers disease to unveil novel biological insights. medRxiv (preprint). 2026. doi:10.64898/2026.02.10.26344393.
BibTeX
@article{cunha2026-beffb111,
author = {Cunha, C. and Garcia-Urena, M. and Martinez, R. and Romero-Lado, M. J. and Fernandez, M. V. and Andreassen, O. A. and Sims, R. and Tsolaki and others},
title = {{Genomics link obesity and type 2 diabetes to Alzheimers disease to unveil novel biological insights}},
journal = {medRxiv (preprint)},
year = {2026},
doi = {10.64898/2026.02.10.26344393},
url = {https://doi.org/10.64898/2026.02.10.26344393}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- These findings elucidate shared cardiometabolic correlates with AD, prioritizes biological pathways, and reveal computationally-nominated drug candidates for preclinical testing.
Why it matters
This genomic analysis linked obesity and type 2 diabetes to Alzheimer's disease through shared genes, mostly in peripheral immune and metabolic tissues, and nominated drug candidates for preclinical testing. The findings are computational and have not been tested as treatments in people.
New to this subject? Start with our plain-English guide: Digital health →
Study details
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 26 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 24 of the 94 points we could judge it on, which is 26 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv (preprint)) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Ruth J. F. Loos: h-index 174 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Oxford: institution h-index 2,205 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 37 institution(s) in 13 countries |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 24 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 24 of the 94 points we could judge it on is 26 out of 100. |
| Total | 26 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Related studies in Digital health tools from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.